A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01946789
• Other study ID #: CITN06-ALT-803
• Secondary ID: U01CA154967
• Status: Completed
• Phase: Phase 1
• Start date: May 2014
• Est. completion date: December 2017

Study information

• Verified date: April 2019
• Source: Altor BioScience
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer

Description:

This trial will investigate the safety and immunogenicity, immunomodulatory properties, and clinical benefits of treatment with weekly doses of ALT-803 in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: December 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

ENTRY CRITERIA:

DISEASE CHARACTERISTICS:

• Histological or cytological confirmed malignancy in the following disease groups:

melanoma that is metastatic or unresectable, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which standard curative or palliative measures do not exist or are no longer effective.

• Primary site may be cutaneous or unknown, but mucosal and ocular primaries are excluded.

• Patients with non-small lung cancer must have had prior EGFR and ALK testing. Patients with sensitizing mutations in EGFR or ALK rearrangements should have been treated with prior targeted agents and have had progression or discontinued due to toxicity from these agents.

• No patients with known brain metastases.

PRIOR/CONCURRENT THERAPY:

• At least one prior therapy using an agent with the potential for prolonged remission.

• Patients with BRAF v600 mutation should be excluded or may be included after experiencing progression following treatment with BRAF inhibitor regimen or if they consent to forgo FDA-approved therapies that increase median survival.

• At least 4 weeks from last dose of prior chemotherapy or immunomodulator therapy with full recovery of acute toxicities. For patients coming off molecularly-targeted therapy, at least 2 weeks since last dose and recovery from laboratory and constitutional toxicities.

• At least 2 weeks from completion of prior radiation therapy with full recovery from toxicities.

• At least 4 weeks from last dose of prior investigational therapy with recovery to meet baseline eligibility criteria.

• Not receiving any current anticancer therapy

• No patients who have had chemotherapy, targeted therapy, or radiotherapy and have not recovered from acute toxicity to their pretreatment baseline or to a grade 1 level within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. For resolution of autoimmune toxicity from prior immune therapy, patients must be off steroids for at least 30 days without relapse of autoimmune toxicity, or it must be at least 30 days from their last dose of infliximab or related immunosuppressive therapy without relapse of autoimmune toxicity.

• No patients who are receiving any other investigational agents.

• No patients who are receiving chronic systemic or regular inhaled corticosteroid use within 7 days prior to initiation of protocol therapy.

• No immunosuppressive therapy within 30 days prior to treatment start.

PATIENT CHARACTERISTICS

• Age >18 years

• Both men and women of all races and ethnic groups are eligible.

Performance Status

• ECOG performance status =1

• Life expectancy of greater than 6 months.

Bone Marrow Function

• leukocytes =3,000/mcL

• absolute lymphocyte count =500/mcL

• absolute neutrophil count =1,000/mcL (without hematopoietic growth factors)

• platelets =100,000/mcL (without transfusion)

• hemoglobin = 10 gm/dL (may be transfused but must be stable without clinical evidence of ongoing blood loss or hemolysis)

Hepatic Function

• total bilirubin within normal institutional limits

• AST(SGOT)/ALT(SGPT) =2.5 × institutional upper limit of normal

Kidney Function

• Creatinine within normal institutional limits OR

• Creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

Pulmonary Function

• No history of severe COPD or emphysema or interstitial lung disease currently on home supplemental oxygen. Patients with NSCLC with stable COPD or emphysema not requiring supplemental oxygen are eligible.

Cardiac Function

• No symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. Patients who have underlying risk factors for cardiac disease should be excluded or undergo clearance stress-based cardiac function testing. The pre-treatment QTc must be <500 msec.

• No class II or greater congestive heart failure as described in the New York Heart Association Functional Classification criteria or serious arrhythmias likely to increase the risk of cardiac complications of cytokine therapy.

Other

• Women of child-bearing potential and men must agree to use adequate contraception.

• Ability to understand and the willingness to sign a written informed consent document.

• No uncontrolled inter-current illness or psychiatric illness/social situations that would limit compliance with study requirements.

• No pregnant women.

• No HIV-positive patients.

• No positive hepatitis C serology or active hepatitis B infection.

• No active bacterial or fungal infection.

• No inability to home monitor blood pressure.

• Patients with thyroid disease should be excluded unless euthyroid on suppressive or replacement therapy.

Related Conditions & MeSH terms

• Advanced Solid Tumors

Intervention

Biological:
• ALT-803
Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Locations

Country	Name	City	State
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire
United States	University of Minnesota	Minneapolis	Minnesota
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	University of Washington, Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Altor BioScience	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile and effectiveness of escalating doses of ALT-803	Safety and effectiveness of ALT-803 on the peripheral blood white blood cell (WBC) and absolute lymphocyte (ALC) counts. Defined by the increase in the total number of peripheral lymphocytes during the first cycle. The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which =2 of 6 patients experience a DLT. The efficacy endpoint is the OBD, defined as that which produces an ALC =25,000/µL and/or a total WBC =35,000/µL among 2/3 of patients. For safety, we have also defined an "exceeding OBD" as the occurrence of ALC =35,000/µL and/or WBC =50,000/µL.	9 months
Secondary	To evaluate the effect of escalating doses of ALT-803	On the number and phenotype of peripheral blood mononuclear cells (PBMCs)by multiparameter blood flow, the level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-?) ELISPOT, immunogenicity and pharmacokinetics of ALT-803 assessed by ELISA and overall objective response rate (ORR) and response duration assessed by evidence of antitumor activity as defined by objective responses and the pharmacokinetic and pharmacodynamic profiles of ALT-803	24 months